69 results about "QT interval" patented technology

System comprised of a medical device and method for analyzing physiological and health data and representing the most significant parameters at different levels of detail which are understandable to a lay person and a medical professional. Low, intermediate and high-resolution scales can exchange information between each other for improving the analyses; the scales can be defined according to the corresponding software and hardware resources. A low-resolution Scale I represents a small number of primary elements such as intervals between the heart beats, duration of electrocardiographic PQ, QRS, and QT-intervals, amplitudes of P-, Q-, R-, S-, and T-waves. This real-time analysis is implemented in a portable device that requires minimum computational resources. The set of primary elements and their search criteria can be adjusted using intermediate or high-resolution levels. At the intermediate-resolution Scale II, serial changes in each of the said elements can be determined using a mathematical decomposition into series of basis functions and their coefficients. This scale can be implemented using a specialized processor or a computer organizer. At the high-resolution Scale III, combined serial changes in all primary elements can be determined to provide complete information about the dynamics of the signal. This scale can be implemented using a powerful processor, a network of computers or the Internet. The system can be used for personal or group self-evaluation, emergency or routine ECG analysis, or continuous event, stress-test or bed-side monitoring.

T-wave amplitude and QT interval are derived from patient cardiac signals. Then blood glucose levels are determined based on a combination of the T-wave amplitude and the QT interval. By using a combination of both T-wave-based and QT interval-based signals, blood glucose levels can be reliably detected throughout a wide range of blood glucose levels. Once the blood glucose level has been detected, the implanted device compares the blood glucose level against upper and lower acceptable bounds and appropriate warning signals are generated if the level falls outside the bounds. In one example, wherein an implantable insulin pump is additionally provided, the pump is controlled based on the detected blood glucose level to maintain glucose levels within an acceptable range. A calibration technique is also provided for determining patient-specific parameters for use in the detection of blood glucose levels.

A method of analysing biomedical signals, for example electrocardiograms, by using a Hidden Markov Model for subsections of the signal. In the case of an electrocardiogram two Hidden Markov Models are used to detect respectively the start and end of the QT interval. The relationship between the QT interval and heart rate can be computed and a contemporaneous value for the slope of this relationship can be obtained by calculating the QT / RR relationship for all of the beats in a sliding time window based on the current beat. Portions of electrocardiograms taken on different days can efficiently and accurately be compared by selecting time windows of the ECGs at the same time of day, and looking for similar beats in those time windows.

A method for treatment of cardiac arrhythmias is disclosed. The method comprises the combining of a sodium channel blocking medication and a potassium channel blocking medication into a therapeutic dosage and the delivery of the therapeutic dosage to a patient in treatment of a heart rhythm problem. The heart rhythm problems being treated include atrial fibrillation and atrial or ventricular tachycardia. Preferably, the therapeutic dosage is at least one tablet and the concentration of each medication is determined based upon the heart problem being treated, the underlying heart rate, the QT interval and other comorbid conditions of the patient. A pharmaceutical composition for the therapeutic treatment of cardiac arrhythmias in a patient is also provided having a combination of a sodium channel blocking medication and a potassium channel blocking medication. Under certain conditions of the patient, the composition can also include a beta blocking medication.

An implantable cardiac stimulation device provides long QT interval therapy for preventing abnormal ventricular activation-recovery time and ultimately ventricular arrhythmias. The device includes a sensing circuit that senses intracardiac activity of a heart and that generates electrical signals representing electrical activity of the heart. The device includes a physiologic sensor, such as body motion, or other diurnally varying sensor that reliably detects a diurnal state of the patient (i.e., not the QT interval itself). The device further includes a measuring circuit that measures a QT interval of the electrical signals, a control circuit that determines whether the QT interval is appropriate for the diurnal state, and a pulse generator that delivers pacing pulses to at least one chamber of the heart at a pacing rate when the QT Interval is pathologically too long. Furthermore, the pacing rate control circuit varies the pacing rate of the pulse generator responsive to the measured QT interval according to the measured diurnal state.

Systems and Methods for stratifying relative risks of adverse cardiac events by processing a duration of electrocardiograph recordings generally recorded by a Holter type of device. The duration of electrocardiograph recordings are processed to resolve RR interval related data, QT interval related data, and are fitted to formulas to at least partially establish fitting related measures. The fitting formulas incorporate circadian related periodic factors, and can further incorporate additional processing including utilizing Lissajous analysis techniques, among others.

An implantable medical device provides ventricular pacing capabilities and optimizes AV intervals for multiple purposes. In general, intrinsic conduction is promoted by determining when electromechanical systole (EMS) ends and setting an AV interval accordingly. EMS is determined utilizing various data including QT interval, sensor input, and algorithmic calculations.

This invention is directed to a method of treating opioid or opioid-like drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with noribogaine at a dosage that provides an average serum concentration of 50 ng / mL to 180 ng / mL under conditions where the QT interval prolongation does not exceed about 50 milliseconds.

An implantable medical device provides ventricular pacing capabilities and optimizes AV intervals for multiple purposes. In general, intrinsic conduction is promoted by determining when electromechanical systole (EMS) ends and setting an AV interval accordingly. EMS is determined utilizing various data including QT interval, sensor input, and algorithmic calculations.

An implantable medical device provides ventricular pacing capabilities and optimizes AV intervals for multiple purposes. In general, intrinsic conduction is promoted by determining when electromechanical systole (EMS) ends and setting an AV interval accordingly. EMS is determined utilizing various data including QT interval, sensor input, and algorithmic calculations.

A method and apparatus for analyzing the QT interval characteristics of ECG signal data having a succession of waveforms produced by the beating of the heart. ECG signal data is obtained from a patient. The R-R interval and the QT intervals of the waveforms of the ECG signal data are determined. Waveforms of the ECG signal data having a stable heart rate are selected for use in determining the QT interval characteristics. Preferably, the waveforms selected are those having minimum R-R interval standard deviation and minimum R-R interval dispersion. The QT correction (QTc) is computed from the ECG signal data waveforms selected in the foregoing manner or on the basis of clinician editing. The R-R intervals, the QT intervals, and QTc for the heart beats of the selected waveforms are displayed for analysis and diagnosis purposes. The invention can also be used, in an analogous manner, to obtain and display other cardiac data from the ECG waveforms.